Number of the records: 1
Galectin-Carbohydrate Interactions in Biomedicine and Biotechnology
- 1.0503882 - MBÚ 2020 RIV GB eng J - Journal Article
Laaf, D. - Bojarová, Pavla - Elling, L. - Křen, Vladimír
Galectin-Carbohydrate Interactions in Biomedicine and Biotechnology.
Trends in Biotechnology. Roč. 37, č. 4 (2019), s. 402-415. ISSN 0167-7799. E-ISSN 1879-3096
R&D Projects: GA ČR(CZ) GA18-01163S; GA MŠMT(CZ) LTC17005; GA MŠMT(CZ) LTC18038; GA MŠMT(CZ) LTC18041
Institutional support: RVO:61388971
Keywords : chemoenzymatic synthesis * glycodendrimers * glycoproteins
OECD category: Biochemistry and molecular biology
Impact factor: 14.343, year: 2019
Method of publishing: Limited access
https://www.sciencedirect.com/science/article/pii/S0167779918302646?via%3Dihub
Cellular communication events are mediated by interactions between cell-surface sugars and lectins, which are carbohydrate-binding proteins. Galectins are beta-galactosyl-binding lectins that bridge molecules by their sugar moieties, forming a signaling and adhesion network. Severe changes in glycosylation and galectin expression accompany major processes in oncogenesis, cardiovascular disorders, and other pathologies, making galectins attractive therapeutic targets. Here we discuss advanced strategies of chemo-enzymatic carbohydrate synthesis for creating lead glycomimetics and (neo-) glycoconjugates for galectin-1 and -3 targeting in biomedicine and biotechnology. We will describe the challenges and bottlenecks on the route into biomedical and biotechnological practice and present the first clinical candidates. The coming era will see an exciting translation of selective well-defined high-affinity galectin ligands from bench to bedside.
Permanent Link: http://hdl.handle.net/11104/0295654
File Download Size Commentary Version Access Laaf TiB.pdf 9 4.1 MB Author´s preprint require
Number of the records: 1